Certified Clinical Hemodialysis Technician (CCHT) Practice Exam 2025 – The All-in-One Guide to Exam Success!

The preferred phosphate binder for controlling hyperphosphatemia with fewer side effects in patients with end-stage renal disease (ESRD) is Lanthanum carbonate. This medication works effectively to lower phosphate levels in patients who are unable to excrete phosphate due to kidney failure. One of the significant advantages of Lanthanum carbonate is its ability to bind phosphate without introducing excess calcium into the patient's system. This is particularly important for patients with ESRD, as they are already at risk for elevated calcium levels, which can lead to vascular calcification and other complications.

Unlike other phosphate binders, Lanthanum carbonate does not cause aluminum accumulation, which can lead to toxicity over time, particularly affecting bone and neurological health. Additionally, patients often tolerate Lanthanum carbonate well, reporting fewer gastrointestinal side effects compared to alternatives like calcium-based binders or aluminum-based options. This makes it a preferred choice in managing hyperphosphatemia while minimizing additional health risks associated with the treatment.